231 related articles for article (PubMed ID: 25720397)
41. Diagnostic Validity Comparison Between Criteria Based on CSF Alzheimer's Disease Biomarkers.
Blanco-Cantó ME; Monge-Argilés JA; Pérez-Cejuela C; Badía C; Gabaldón L; Muñoz-Ruíz C; Sánchez-Payá J; Gasparini-Berenguer R; Leiva-Santana C
Am J Alzheimers Dis Other Demen; 2017 Mar; 32(2):101-107. PubMed ID: 28191798
[TBL] [Abstract][Full Text] [Related]
42. Event-related Potentials Improve the Efficiency of Cerebrospinal Fluid Biomarkers for Differential Diagnosis of Alzheimer's Disease.
Babić Leko M; Krbot Skorić M; Klepac N; Borovečki F; Langer Horvat L; Vogrinc Ž; Sonicki Z; Hof PR; Šimić G
Curr Alzheimer Res; 2018; 15(13):1244-1260. PubMed ID: 30207231
[TBL] [Abstract][Full Text] [Related]
43. Prediction of Alzheimer disease in subjects with amnestic and nonamnestic MCI.
Vos SJ; van Rossum IA; Verhey F; Knol DL; Soininen H; Wahlund LO; Hampel H; Tsolaki M; Minthon L; Frisoni GB; Froelich L; Nobili F; van der Flier W; Blennow K; Wolz R; Scheltens P; Visser PJ
Neurology; 2013 Mar; 80(12):1124-32. PubMed ID: 23446677
[TBL] [Abstract][Full Text] [Related]
44. Analysis of combined CSF biomarkers in AD diagnosis.
De Riva V; Galloni E; Marcon M; Di Dionisio L; Deluca C; Meligrana L; Bolner A; Perini F
Clin Lab; 2014; 60(4):629-34. PubMed ID: 24779297
[TBL] [Abstract][Full Text] [Related]
45. Combining Cerebrospinal Fluid Biomarkers and Neuropsychological Assessment: A Simple and Cost-Effective Algorithm to Predict the Progression from Mild Cognitive Impairment to Alzheimer's Disease Dementia.
Mazzeo S; Santangelo R; Bernasconi MP; Cecchetti G; Fiorino A; Pinto P; Passerini G; Falautano M; Comi G; Magnani G
J Alzheimers Dis; 2016 Oct; 54(4):1495-1508. PubMed ID: 27589522
[TBL] [Abstract][Full Text] [Related]
46. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
[TBL] [Abstract][Full Text] [Related]
47. APOE ε4 carriers may undergo synaptic damage conferring risk of Alzheimer's disease.
Sun X; Dong C; Levin B; Crocco E; Loewenstein D; Zetterberg H; Blennow K; Wright CB;
Alzheimers Dement; 2016 Nov; 12(11):1159-1166. PubMed ID: 27321472
[TBL] [Abstract][Full Text] [Related]
48. Stage-dependent agreement between cerebrospinal fluid proteins and FDG-PET findings in Alzheimer's disease.
Yakushev I; Muller MJ; Buchholz HG; Lang U; Rossmann H; Hampel H; Schreckenberger M; Fellgiebel A
Curr Alzheimer Res; 2012 Feb; 9(2):241-7. PubMed ID: 22044023
[TBL] [Abstract][Full Text] [Related]
49. Comparison of Commonly Measured Plasma and Cerebrospinal Fluid Proteins and Their Significance for the Characterization of Cognitive Impairment Status.
Rehman H; Ang TFA; Tao Q; Espenilla AL; Au R; Farrer LA; Zhang X; Qiu WQ;
J Alzheimers Dis; 2024; 97(2):621-633. PubMed ID: 38143358
[TBL] [Abstract][Full Text] [Related]
50. A Decade of Cerebrospinal Fluid Biomarkers for Alzheimer's Disease in Belgium.
Somers C; Struyfs H; Goossens J; Niemantsverdriet E; Luyckx J; De Roeck N; De Roeck E; De Vil B; Cras P; Martin JJ; De Deyn PP; Bjerke M; Engelborghs S
J Alzheimers Dis; 2016 Aug; 54(1):383-95. PubMed ID: 27567807
[TBL] [Abstract][Full Text] [Related]
51. Alzheimer's Disease Assessment Scale-Cognitive subscale variants in mild cognitive impairment and mild Alzheimer's disease: change over time and the effect of enrichment strategies.
Podhorna J; Krahnke T; Shear M; Harrison JE;
Alzheimers Res Ther; 2016 Feb; 8():8. PubMed ID: 26868820
[TBL] [Abstract][Full Text] [Related]
52. Erlangen Score as a tool to predict progression from mild cognitive impairment to dementia in Alzheimer's disease.
Baldeiras I; Santana I; Leitão MJ; Vieira D; Duro D; Mroczko B; Kornhuber J; Lewczuk P
Alzheimers Res Ther; 2019 Jan; 11(1):2. PubMed ID: 30611311
[TBL] [Abstract][Full Text] [Related]
53. SUCLG2 identified as both a determinator of CSF Aβ1-42 levels and an attenuator of cognitive decline in Alzheimer's disease.
Ramirez A; van der Flier WM; Herold C; Ramonet D; Heilmann S; Lewczuk P; Popp J; Lacour A; Drichel D; Louwersheimer E; Kummer MP; Cruchaga C; Hoffmann P; Teunissen C; Holstege H; Kornhuber J; Peters O; Naj AC; Chouraki V; Bellenguez C; Gerrish A; ; ; Heun R; Frölich L; Hüll M; Buscemi L; Herms S; Kölsch H; Scheltens P; Breteler MM; Rüther E; Wiltfang J; Goate A; Jessen F; Maier W; Heneka MT; Becker T; Nöthen MM
Hum Mol Genet; 2014 Dec; 23(24):6644-58. PubMed ID: 25027320
[TBL] [Abstract][Full Text] [Related]
54. Neurodegenerative disease biomarkers Aβ
Chen JA; Fears SC; Jasinska AJ; Huang A; Al-Sharif NB; Scheibel KE; Dyer TD; Fagan AM; Blangero J; Woods R; Jorgensen MJ; Kaplan JR; Freimer NB; Coppola G
Brain Behav; 2018 Feb; 8(2):e00903. PubMed ID: 29484263
[TBL] [Abstract][Full Text] [Related]
55. Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia.
Buchhave P; Minthon L; Zetterberg H; Wallin AK; Blennow K; Hansson O
Arch Gen Psychiatry; 2012 Jan; 69(1):98-106. PubMed ID: 22213792
[TBL] [Abstract][Full Text] [Related]
56. Conflicting cerebrospinal fluid biomarkers and progression to dementia due to Alzheimer's disease.
Alexopoulos P; Werle L; Roesler J; Thierjung N; Gleixner LS; Yakushev I; Laskaris N; Wagenpfeil S; Gourzis P; Kurz A; Perneczky R;
Alzheimers Res Ther; 2016 Dec; 8(1):51. PubMed ID: 27931251
[TBL] [Abstract][Full Text] [Related]
57. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
[TBL] [Abstract][Full Text] [Related]
58. Florbetapir positron emission tomography and cerebrospinal fluid biomarkers.
Hake A; Trzepacz PT; Wang S; Yu P; Case M; Hochstetler H; Witte MM; Degenhardt EK; Dean RA;
Alzheimers Dement; 2015 Aug; 11(8):986-93. PubMed ID: 25916563
[TBL] [Abstract][Full Text] [Related]
59. Genome-wide association study of Alzheimer's disease endophenotypes at prediagnosis stages.
Chung J; Wang X; Maruyama T; Ma Y; Zhang X; Mez J; Sherva R; Takeyama H; ; Lunetta KL; Farrer LA; Jun GR
Alzheimers Dement; 2018 May; 14(5):623-633. PubMed ID: 29274321
[TBL] [Abstract][Full Text] [Related]
60. Factors that influence the levels of cerebrospinal fluid biomarkers in memory clinic patients.
Knapskog AB; Eldholm RS; Braekhus A; Engedal K; Saltvedt I
BMC Geriatr; 2017 Sep; 17(1):210. PubMed ID: 28893185
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
